10 Jun 2013 Posted in News Release By Press Office
The Scorecard, released by the NHS Health and Social Care Information Centre (HSCIC), includes a number of new medicines which were not included in the January report.
The ABPI has welcomed the inclusion of more data on newly introduced innovative medicines as it suggests the development of the Scorecard is progressing in the right direction. In future versions it is hoped that a more extensive Scorecard will illustrate a more comprehensive picture of the use of NICE appraised medicines, so that any unwarranted variation in treatments can be addressed for the good of patients.
To this end, the ABPI would like future Scorecards to include further data sets, so clinicians and members of the public can gain a fuller understanding of how well innovation is being adopted to improve patient care.
Specifically, we would like to see future Scorecards:
Commenting, Stephen Whitehead, Chief Executive of the ABPI, said:
"I am pleased that the latest Innovation Scorecard has built on the first publication in January and we are now seeing more new medicines included in the report. But in future updates, including the next Scorecard set for publication in September; we want to see its depth and scope increase significantly. This is essential because if the Scorecard is to be a genuine driver of change, it must be comprehensive and detailed enough for people to make meaningful judgements about the state of innovation in the NHS.
"I think it is also important to remember that the Innovation Scorecard is one of a number of important policy tools that are in development to improve the uptake of new medicines. The wider Innovation, Health and Wealth (IHW) agenda, of which the Scorecard is a part, has seen great progress since it was first announced by Government 18 months ago. We now have a number of new initiatives such as Academic Health Service Networks which simply did not exist before to spur innovation in the NHS and which help drive improvements in the use of NICE appraised medicines at a local level for the benefit of patients. But it is essential now that the new healthcare system, which is operating in a very different environment under NHS England, remains focussed on delivering IHW so that UK patients can access innovative treatments which they are too often denied."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.